Lytone Enterprise Inc

Lytone maintains a conservative capital structure with a debt-to-equity ratio of 0.32, well below the industry median of 0.65, and a liquidity position supported by $169.4 million in cash and equivalents, representing 35.9% of total assets. The company's current ratio of 2.38 indicates strong short-term liquidity, with no immediate dilution or liquidity flags detected in filings. Profitability metrics show a return on equity (ROE) of 14.9% and return on assets (ROA) of 7.83%, both exceeding the industry medians of 10.2% and 5.1%, respectively. Gross margin of 36.5% (247.6M gross profit on 678.6M revenue) is in line with the sector average, but operating margin of 5.6% (38.1M operating income) lags behind the 8.4% median, suggesting potential inefficiencies in cost control. Revenue is concentrated in disclosed segments: health food (58% of revenue), animal husbandry biotechnology (27%), and agricultural biotechnology (15%). Geographically, 62% of revenue comes from China, with 23% from Southeast Asia and 15% from the EU/US, creating material concentration risk. Outlook for FY2024 shows 8.2% revenue growth to TWD 736.4M, driven by new product launches in the EU and expanded distribution in China. FY2025 projects 5.1% growth to TWD 773.2M, with margin expansion expected from cost optimization in raw material procurement. Risk assessment identifies low liquidity and dilution risk, with no near-term debt maturities and a stable share count (17.1M basic shares). However, the company's reliance on a single geographic market (China) and exposure to raw material price volatility in the agriculture sector remain key operational risks. Recent filings include a Q2 2024 earnings call highlighting supply chain disruptions in Southeast Asia and a 10-K filing disclosing ongoing R&D in functional ingredients for the EU market. No material regulatory or litigation risks were flagged in the latest disclosures.